Inorial (Bilastine)

Bilastine selectively blocks peripheral H1 receptors on mast cells and conjunctival tissues. By preventing histamine from binding, it stops the cascade that leads to vasodilation, increased permeability, and nerve activation, thereby reducing redness, swelling, and itching in the eye.

The dosing regimen for Inorial is determined by the prescribing clinician based on the patient’s condition and response. Typically, a single drop is instilled in the affected eye(s) as directed, but the exact frequency and duration are set by the healthcare professional.

Safety data for bilastine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To place an order, submit an enquiry on the Inorial product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Inorial (bilastine) is a second‑generation H1 antagonist that offers rapid symptom relief with a low incidence of sedation compared with first‑generation agents. Compared with alternatives such as olopatadine, bilastine provides comparable efficacy for allergic conjunctivitis while maintaining a favorable safety profile and minimal systemic absorption.

Inorial should be stored at room temperature, preferably below 25 °C, in its original packaging. Protect the container from moisture and direct sunlight. Do not freeze the product, and keep it out of reach of children.

Inorial is applied as an eye drop. The patient should wash hands, tilt the head back, gently pull down the lower eyelid, and instill one drop into the conjunctival sac of the affected eye(s). Close the eyes gently for a few seconds and avoid blinking excessively.

The most serious risks include severe allergic reactions such as anaphylaxis, acute angle‑closure glaucoma, and significant vision changes like blurred vision or photophobia. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden vision loss, or intense eye pain.

Inorial should not be used by individuals with a known hypersensitivity to bilastine or any component of the formulation. It is also contraindicated in children under two years of age, and caution is advised in patients with severe hepatic impairment or a history of angle‑closure glaucoma.